8 hours Ago By ABMN Staff
Vaxcyte, Inc. ( NASDAQ:PCVX – Free Report ) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Vaxcyte in a report released on Tuesday, April 22nd. Cantor Fitzgerald analyst C.
Gould forecasts that the company will post earnings of ($5.10) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. PCVX has been the topic of a number of other research reports.
The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.
Bank of America decreased their target price on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st.
Evercore ISI raised Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th.
Finally, Guggenheim reiterated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock.
According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $136.50. Vaxcyte Price Performance Shares of PCVX opened at $34.
51 on Thursday. The company’s 50-day moving average is $56.56 and its 200-day moving average is $80.
88. The firm has a market capitalization of $4.45 billion, a PE ratio of -7.
50 and a beta of 1.26. Vaxcyte has a fifty-two week low of $27.
66 and a fifty-two week high of $121.06. Vaxcyte ( NASDAQ:PCVX – Get Free Report ) last posted its quarterly earnings results on Tuesday, February 25th.
The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.
14. Insider Activity In other news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.
27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.
37. The trade was a 4.91 % decrease in their position.
The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . In the last three months, insiders sold 24,000 shares of company stock worth $1,946,720. 3.
10% of the stock is currently owned by company insiders. Institutional Trading of Vaxcyte Several large investors have recently made changes to their positions in the company. Vanguard Group Inc.
lifted its stake in Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc.
now owns 11,961,687 shares of the company’s stock worth $979,184,000 after purchasing an additional 521,204 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of Vaxcyte by 26.8% during the 4th quarter.
Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after buying an additional 1,312,302 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Vaxcyte by 3.
0% during the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company’s stock worth $234,884,000 after buying an additional 82,997 shares during the last quarter.
Geode Capital Management LLC boosted its stake in Vaxcyte by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company’s stock valued at $229,495,000 after buying an additional 102,106 shares in the last quarter.
Finally, Alliancebernstein L.P. grew its position in Vaxcyte by 8.
1% in the fourth quarter. Alliancebernstein L.P.
now owns 1,779,362 shares of the company’s stock valued at $145,659,000 after acquiring an additional 133,448 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.
About Vaxcyte ( Get Free Report ) Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter ..
